Wasdell Group invests £500k in new microbiological and analytical lab

By Murielle Gonzalez | Published: 11-Jun-2018

New 1,200 sq ft facility in Newcastle to support Wasdell's planned move into the manufacture of sterile products later this year

UK's Wasdell Group, the outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, is investing £500k in a new laboratory at its site in Newcastle.

The purpose-built 1,200 sq ft facility will allow Wasdell to offer in-house microbiological and analytical services to its customers and will support the business’ manufacturing, packaging and quality control (QC) teams.

The investment follows on from a growing customer base as well as an increase in the number of pre-clinical development projects that have recently been awarded to Wasdell.

Daniel Tedham, MD at Wasdell, said: “This latest investment is part of a client-centric strategy that ensures we continue to offer existing and new clients a fast and efficient service that meets their end-to-end supply needs.

“We’ve seen a notable increase in demand for analytical support from our existing clients and the investment in our microbiological capabilities has been driven by our planned move into the manufacture of sterile products later this year.”

Lab capabilities

The investment is the first phase of the company’s ongoing expansion strategy to bolster its laboratory capabilities and ensure seamless internal operations. The second phase will include the opening of a new laboratory facility in Ireland to futureproof Wasdell’s release testing offering for the European market in the event of a hard Brexit.

A microbiological laboratory team will deliver in-house environmental monitoring, sample analysis, water testing, microbiological identification analysis, component testing and growth promotion testing.

The lab will also offer analytical capabilities for chemical, physical and microbiological analysis including HPLC, FTIR and wet chemistry with QC testing of raw materials, drug substances (currently Schedule III with capacity to cater for Schedule II products) and drug products in accordance with pharmacopoeial monographs and client methods.

The facility is the latest addition to the company’s manufacturing site in Newcastle. The 26,000 sq ft facility is MHRA approved for pharmaceutical manufacturing and has a Home Office Controlled Drugs license with onsite storage facilities.

It follows the recent announcement of the company’s new €30m pharmaceutical facility in Dundalk, Ireland, which will offer QC import testing, a variety of current and novel packaging technologies as well as storage and distribution.

You may also like